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Abstract
Background: Bacterial pneumonia in pigs occurs widely and requires antimicrobial therapy. It is commonly caused
by the pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida. Marbofloxacin is an antimicrobial drug
of the fluoroquinolone class, licensed for use against these organisms in the pig. In recent years there have been
major developments in dosage schedule design, based on integration and modelling of pharmacokinetic (PK) and
pharmacodynamic (PD) data, with the objective of optimising efficacy and minimising the emergence of resistance.
From in vitro time-kill curves in pig serum, PK/PD breakpoint Area under the curve (AUC) 24h /minimum inhibitory
concentration (MIC) values were determined and used in conjunction with published PK, serum protein binding
data and MIC distributions to predict dosages based on Monte Carlo simulation (MCS).
Results: For three levels of inhibition of growth, bacteriostasis and 3 and 4log10 reductions in bacterial count, mean
AUC24h/MIC values were 20.9, 45.2 and 71.7 h, respectively, for P. multocida and 32.4, 48.7 and 55.5 h for A.
pleuropneumoniae. Based on these breakpoint values, doses for each pathogen were predicted for several clinical
scenarios: (1) bacteriostatic and bactericidal levels of kill; (2) 50 and 90% target attainment rates (TAR); and (3) single
dosing and daily dosing at steady state. MCS for 90% TAR predicted single doses to achieve bacteriostatic and
bactericidal actions over 48 h of 0.44 and 0.95 mg/kg (P. multocida) and 0.28 and 0.66 mg/kg (A. pleuropneumoniae).
For daily doses at steady state, and 90% TAR bacteriostatic and bactericidal actions, dosages of 0.28 and 0.59 mg/kg
(P. multocida) and 0.22 and 0.39 mg/kg (A. pleuropneumoniae) were required for pigs aged 12 weeks. Doses were
also predicted for pigs aged 16 and 27 weeks.
Conclusions: PK/PD modelling with MCS approaches to dose determination demonstrates the possibility of
tailoring clinical dose rates to a range of bacterial kill end-points.
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Background
Marbofloxacin is a synthetic third-generation fluoro-
quinolone, developed for sole veterinary use. It has high
bioavailability when administered to pigs by intramuscu-
lar injection [1]. It accumulates in the cytosol of macro-
phages, leucocytes, neutrophils, epithelial lining fluid
and plasma [2, 3]. Marbofloxacin, as a lipid-soluble or-
ganic acid and low to moderate plasma protein binding,
achieves good tissue penetration and a high volume of
distribution [4]. Concentrations in the lung, liver and
kidney exceed those in plasma. However, concentrations
in the biophase, the pulmonary epithelial lining fluid in
pigs with pneumonia, at steady state will be determined
by free drug concentration in plasma. This has been
shown to be 50.6% of total concentration in pigs [4].
Lees and Aliabadi [4] reported that marbofloxacin exerts
a prolonged post-antibiotic (PAE) and sub-minimum
inhibitory concentration (MIC) PAE effects. It has a broad
spectrum of antibacterial activity, is bactericidal and exerts
a concentration-dependent killing action [5]. The anti-
microbial spectrum includes Brucella spp. and Myco-
plasma spp. Marbofloxacin is licensed for treatment of
pneumonia caused by the pig pneumonia pathogens,
Actinobacillus pleuropneumoniae, Pasteurella multocida
and Streptococcus suis [6]. Bacterial pneumonia in pigs is
also caused by other organisms, including Bordetella
bronchiseptica and Mycoplasma hyopneumoniae.
Over the last two decades, there have been major
advances in designing dosage schedules of antimicrobial
drugs, based on integration and modelling of pharmaco-
dynamic (PD) and pharmacokinetic (PK) data. These ap-
proaches have provided novel strategies for predicting
drug dosages that optimise efficacy and minimise oppor-
tunities for the emergence and subsequent spread of re-
sistance [6–15]. Optimising dosage may involve reducing
doses which may be too high as well as increasing doses
when they are too low.
Many authors have proposed that, for fluoroquino-
lones as a group, the integrated PK/PD indices correlat-
ing with successful therapeutic outcome are maximum
plasma concentration (Cmax)/MIC and area under
plasma concentration-time curve (AUC24h)/MIC ratios
[5, 7, 8, 11, 16, 17].
The PD parameter most commonly used in establish-
ing the potency of antimicrobial drugs is MIC, the low-
est concentration based on two-fold dilutions, inhibiting
visible bacterial growth after 24 h incubation under
standard conditions (Clinical and Laboratory Standards
Institute (CLSI) M31-A3) [18]. Most laboratories use the
internationally recommended CLSI guidelines to ensure
standardisation [13]. However, these guidelines have lim-
itations regarding accuracy, because they involve the use
of doubling dilutions, giving potential for up to 100%
error on single isolate estimates. For many purposes, this
is acceptable, and indeed is necessary, when large numbers
of isolates are to be examined. However, it may not always
be appropriate when MIC is correlated with PK data as a
basis for PK/PD breakpoint determination. Therefore,
based on methods previously described [19–21] five over-
lapping sets of two-fold dilutions were used in this study to
reduce inaccuracy from up to 100% to no more than 20%.
The mutant prevention concentration (MPC) was used as
an additional indicator of potency to MIC; it is defined as
the lowest drug concentration required for preventing the
growth of the least susceptible cells present in high density
bacterial populations.
A second consideration is that CLSI and European
Union Committee on Antimicrobial Testing (EUCAST)
methods of MIC determination require the use of broths
formulated to optimize the growth of each species of
bacteria. Therefore, there is almost universal use of
internationally recognised guidelines, methods and stan-
dards for MIC determination. However, when the object-
ive of potency determination is prediction of dosage for
clinical efficacy, based on PK/PD breakpoints, conditions
should be representative of in vivo pathological circum-
stances. Zeitlinger et al. [22] commented that “bacteria
with appropriate and well-defined growth in the selected
medium should be employed” and “in order to be able to
extrapolate data from various models to in vivo situations,
models should always attempt to mimic physiological
conditions as closely as possible”.
Whilst serum is not identical to extravascular infection
site fluids, it is likely to be closer in chemical compos-
ition to the biophase than broths, and indeed in im-
munological constituents also [22, 23]. A comparison of
broth MICs with potency determined in biological fluids
is therefore relevant to PK/PD breakpoint estimation.
For some drugs and pathogens, calculation of a scaling
factor to bridge between broth and serum MICs may be
warranted [7, 15, 23, 24]. In this investigation MICs and
time-kill data were generated for marbofloxacin in pig
serum. They were thus determined with reasonable
accuracy and in a biological matrix.
With the objectives of: extending the therapeutic life
of older antimicrobial drugs; ensuring their prudent use
and; minimising the emergence of resistance, there have
been many proposals to re-evaluate dose schedules that
were set, in many instances, prior to the application of
PK/PD breakpoints [8–11, 13–15, 19]. For example,
Mouton et al. [9] have described the EUCAST approach
to dosage re-evaluation. In summary, these authors have
proposed that a sound approach to setting dose sched-
ules is to link PK parameters and variables with appro-
priate indices of potency, applying the general equation
for systemically acting drugs (Fig. 1) [19, 25, 26].
The aims of this study were: (1) to integrate published
PK variables for the pig with MIC data for pig pathogens
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obtained in our laboratory in order to generate values of
the three PK/PD parameters, Cmax/MIC, Cav/MIC and
T > MIC, for A. pleuropneumoniae and P. multocida; (2)
to model data from time-kill studies of A. pleuropneu-
moniae and P. multocida, using multiples of MIC over
the range 0.25–8.0 MIC, in order to generate PK/PD
breakpoint values of AUC24h/MIC for three levels of
bacterial kill, bacteriostasis, bactericidal and 4log10 re-
duction in inoculum count; (3) to use published PK data
and PK/PD breakpoints, with serum protein binding
data and literature MIC distributions, in Monte Carlo
simulations (MCS) to predict dose schedules required
for: (a) bacteriostatic and bactericidal levels of kill; (b)
for 50 and 90% Target Attainment rate (TAR); and (c)
for single dosing and daily dosing at steady state.
Methods
Minimum inhibitory concentration
Twenty isolates each of A. pleuropneumoniae and P. mul-
tocida were obtained from EU cases of pig pneumonia.
These were screened for ability to grow logarithmically in
broths and pig serum. Of those exhibiting logarithmic
growth in both matrices, MICs in broth were determined
by microdilution using two-fold dilutions. From the sensi-
tive isolates, six of each species were selected and MICs
re-determined, using artificial broths (Cation Adjusted
Mueller Hinton broth for P. multocida and Columbia
broth for A. pleuropneumoniae) in accordance with CLSI
guidelines, except that five sets of overlapping 2-fold serial
dilutions of marbofloxacin were prepared, as described by
Dorey et al. [27]. In addition, the guidelines were adapted
to additionally use pig serum in place of broth to enable
comparison of the two matrices.
PK/PD breakpoint determination
For the six isolates each of A. pleuropneumoniae and P.
multocida, eight marbofloxacin concentrations, as multi-
ples of MIC, ranging from 0.25 to 8xMIC, were used in
time-kill studies over 24 h incubation periods. Determi-
nations were made separately in serum and broth (CB
for A. pleuropneumoniae and CAMHB for P. multocida),
as previously described [27, 28]. Each test was repeated
in triplicate for the six isolates of each species in both
growth matrices. The time-kill curves established bac-
teriostatic, bactericidal and 4log10 reductions in count at
24 h; based on the sigmoidal Emax equation (Fig. 2) the
Fig. 1 Formula for calculation of the daily antimicrobial drug dose based on PK and PD variables
Fig. 2 The sigmoidal Emax equation used to model time-kill data by non-linear regression [27]
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data were modelled to provide AUC24h/MIC breakpoint
values for these three levels of growth inhibition.: E = 0,
bacteriostatic, that is 0log10 reduction in CFU/mL after
24 h incubation; E = −3, bactericidal, 3log10 reduction in
CFU/mL; and E = −4, 4log10 reduction in bacterial count.
Dose prediction
Deterministic approach
For dose prediction using the deterministic approach,
mean PK values were obtained from Schneider et al. [1]
and PK/PD breakpoint values were used from the present
study, together with MIC90 values for P. multocida and A.
pleuropneumoniae for marbofloxacin obtained from de
Jong et al. [29] (Fig. 3).
Monte Carlo simulation
As the PK/PD index that best predicts efficacy for mar-
bofloxacin is the ratio AUC24h/MIC, the equation used
to calculate dose was:
Dose per dayð Þ ¼
Cl  AUC 24hð ÞMICe  MICdistribution
f u  F
where Cl = body clearance per h, AUC(24h)/MICe (in h) = ra-
tio of experimentally determined area under the serum
concentration-time curve over 24 h to the MIC (MICe) of
the experimental isolates – six per species - (i.e. the PK/PD
breakpoint), MICdistribution = distribution of MICs from
epidemiological literature [29], fu (from 0 to 1) = fraction
of drug not bound to serum protein and F = bioavailability
(from 0 to 1). Thus, calculation of dose depends on: (1) as-
sessment of both PK (Cl, F, fu,) and PD (MIC) properties;
and (2) determination of an appropriate breakpoint value
of the AUC(24h)/MIC ratio. This Equation is appropriate
for determining daily dosage once steady state has been
reached. However, the calculated dose when the initial
drug concentration in serum is zero, is very likely to be
higher than the dose determined for maintaining the
steady state concentration.
Loading doses were calculated for three time periods,
0–24, 0–48 and 0–72 h [7]; the formulae for calculation
of dosage for a 48 h period are presented in Fig. 4.
All dosages were computed using Monte Carlo simula-
tion in Oracle Crystal Ball (Oracle Corporation, Red-
wood Shores, CA, USA), for TAR of 50 and 90%. The
probabilities of distribution for the dosage estimation
were run for 50,000 simulated trials. Data input com-
prised: 1) marbofloxacin whole body clearance scaled by
bioavailability; clearance data were obtained from the
equation Clearance = Dose/AUC, for pigs of three ages
[27, 16 and 2 weeks]; 2) drug binding to serum protein
[27]; 3) AUC24h/MIC breakpoints derived from time-kill
curves; and 4) MIC field distribution data [1] (Fig.3). For
the MIC field distributions, values were corrected using
the serum:broth MIC ratio, as the reported MIC literature
values were determined in broth.
Results
Minimum inhibitory concentrations
Geometric mean MIC serum:broth ratios for P. multo-
cida and A. pleuropneumoniae (six isolates of each
species) were 1.12:1 and 0.79:1, respectively. For MPC,
the ratios were 1.32:1 and 0.99:1, respectively. These did
not differ significantly from unity. However, as free drug
concentration in pig serum was previously shown to be
50.6% (Dorey et al. 2016b) [28] and as protein bound
drug is microbiologically inactive, the corrected ratios,
fraction unbound (fu) serum:broth MIC were 0.50:1 and
0.40:1, and 0.67:1 and 0.50:1 for MPC, indicating small
(in microbiological terms) but significantly greater po-
tency of marbofloxacin in serum than in broth.
PK/PD breakpoint values
For each isolate of each organism, growth inhibition
curves were generated in the time-kill studies in broth
and pig serum. Examples are presented in Fig. 5.
From the time-kill curves, PK/PD breakpoints were de-
rived and are presented in Tables 1 (P. multocida) and 2
(A. pleuropneumoniae). For three levels of inhibition of
growth, bacteriostasis and 3 and 4log10 reductions in
bacterial count, mean AUC24h/MIC values were 20.9, 45.2
and 71.7 h, respectively, for P. multocida for serum.
Corresponding broth values were 26.5, 41.8 and 48.9 h.
For A. pleuropneumoniae in serum, breakpoints were
Fig. 3 Marbofloxacin MIC distributions of P. multocida (n = 230) and A. pleuropneumoniae (n = 219) indicating frequency of MICs. MIC data were
generated using CLSI guidelines by de Jong et al. [29]). All isolates were from European countries
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32.4, 48.7 and 55.5 h. and for broth values were 24.8, 42.0
and 54.0 h. Differences between broth and serum, at each
level of kill, were relatively small, despite differences
between broth MICs and serum MICs corrected for
drug binding to serum protein. This is not unex-
pected, as each inhibition curve was derived using
MIC multiples for each fluid.
As a measure of inter-isolate variability, coefficients of
variation were determined. These were small to moder-
ate in magnitude (Tables 1 and 2).
Dividing the AUC24h/MIC ratios by 24 yields concen-
trations, as MIC multiples, producing bacteriostatic,
bactericidal and 4log10 reductions in count; these are the
KPD values. Numerical values were, respectively, 1.10,
1.74 and 2.04 for P. multocida in broth and 0.87, 1.88
and 2.99 for this organism in serum. Corresponding
values for A. pleuropneumoniae were 1.03, 1.75 and 2.25
(broth) and 1.35, 2.03 and 2.31 (serum).
Dose determination at steady state (deterministic
approach)
Clearance and bioavailability data for healthy pigs were
obtained from the literature [1]. Table 3 indicates pre-
dicted doses required, at steady state, to achieve three
levels of kill. Bactericidal levels of kill were obtained with
doses 0.41 mg/kg/day for P. multocida and 0.26 mg/kg/
day for A. pleuropneumoniae.
Dose determination by Monte Carlo simulation
Monte Carlo simulations were conducted using: (1) the
distribution of clearance around the standard deviation,
assuming normal distribution (Schneider et al. 2014) [1];
(2) the distribution of MICs for wild type organisms
[29]; (3) free drug fraction in serum; (4) breakpoint
values of AUC24h/MIC from time-kill studies.
Predicted doses at steady state for 50% and 90% TAR
and three levels of kill are presented in Table 4. Doses
for bactericidal action for P. multocida were 0.43, 0.45
and 0.59 mg/kg, respectively, for pigs aged 27, 16 and
2 weeks. Corresponding values for A. pleuropneumoniae
were somewhat lower, 0.29, 0.30 and 0.39 mg/kg. The
Fig. 4 Formulae for calculation of the loading dose for 48 h duration of action, where eq. a can be expressed as eq. b and simplified as eq. c.
K10 = elimination rate constant; τ = dosing interval in h; Cl48 = body clearance over 48 h; KPD breakpoint = AUC divided by 24; MICDistribution = MICs
determined from epidemiological surveys; F = bioavailability (from 0 to 1); fu = fraction of drug not bound to protein binding
Fig. 5 Example plots of AUC24h/MIC (h) versus change in bacterial
count (log10 CFU/mL) for P. multocida in (a) broth and (b) serum. The
points represent observed values and the curves are lines of best fit
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small numerical differences with age of pigs reflect small
differences in their PK profiles. Differences in predicted
dose for the two bacterial species reflect the differing
distributions of MIC of wild type organisms.
Table 5 indicates calculated doses for single doses of
marbofloxacin administered intramuscularly with three
durations of effect, three levels of kill and TARs of 50 and
90%. For a bacteriostatic action of 24 h duration and 50%
TAR, predicted doses were 0.12 and 0.03 mg/kg for P.
multocida and A. pleuropneumoniae, respectively. For a
TAR of 90%, a bactericidal level of kill and an action over
72 h, the predicted doses were 1.31 and 0.92 mg/kg,
respectively, for P. multocida and A. pleuropneumoniae.
Even for a 4log10 reduction in count and 90% TAR, pre-
dicted doses were relatively low, 2.08 mg/kg (P. multocida)
and 1.14 mg/kg (A. pleuropneumoniae).
Discussion
Pharmacokinetics, pharmacodynamics and PK/PD
integration
Integration of in vitro generated potency estimates with
in vivo PK data has been used extensively to generate
three indices to predict clinical outcome, namely the ra-
tios, Cmax/MIC and AUC24h/MIC and T > MIC, the time
for which concentration exceeds MIC. Integration of
pharmacokinetic and pharmacodynamic data for MPC
are presented in the Additional file 1. All MPC ratios
were much lower than the MIC ratios. From previous
marbofloxacin studies, Cmax/MIC and AUC24h/MIC
ratios provided good correlation with bacteriological
cure in human patients [30, 31]. For fluoroquinolones
used in veterinary medicine, a Cmax/MIC of 8–10 and an
AUC24h/MIC greater than 100–125 h have been pro-
posed [13]. However, other studies have suggested that a
ratio of AUC24h/MIC of 35–50 is effective for Gram-
positive bacteria [32]. Many authors have proposed
achieving numerical values of AUC24h/MIC of 125:1 or
250:1 for gram negative organisms, corresponding to
average concentrations over the dosing interval of 5.2 to
10.4, respectively, as a multiple of MIC.
For marbofloxacin, de Jong et al. [29] reported identical
MIC50 values for both A. pleuropneumoniae and P. multo-
cida of European pig origin of 0.03 μg/mL and identical
MIC90 values of 0.06 μg/mL. Schneider et al. [1] reported
Table 1 P. multocida PK/PD modelling of in vitro marbofloxacin time-kill curves (mean, standard deviation, n = 6)
Parameter (units) Broth Serum
Mean SD (CV%) Mean SD (CV%)
Log E0 (CFU/mL) 2.66 0.26 2.70 0.32
Log Emax (CFU/mL) −7.28 0.37 −5.65 1.43
Log Emax - Log E0 (CFU/mL) −9.95 0.11 −8.35 1.11
Gamma 3.26 1.48 1.95 0.23
AUC24h/MIC for bacteriostatic action (h) 26.5 4.65 (17.5) 20.9 2.31(11.1)
AUC24h/MIC50(h) 38.0 8.05 (21.2) 30.5 5.39 (17.7)
AUC24h/MIC for bactericidal action (h) 41.8 7.79 (18.7) 45.2 5.58 (12.3)
AUC24h/MIC for 4 log10 reduction (h) 48.9 10.8 (22.0) 71.7 34.0 (47.4)
E0 = difference in number of organisms (CFU/mL) in control sample in absence of drug between time 0 and 24 h; Emax = difference in number of organisms (CFU/
mL) in presence of marbofloxacin between time 0 and 24 h; AUC24/MIC50 = concentration producing reduction in count to 50% of the Emax; Gamma = slope of
the curve; detection limit = 33 CFU/mL
Table 2 A. pleuropneumoniae PK/PD modelling of in vitro marbofloxacin time-kill curves (mean, standard deviation, n = 6)
Parameter (units) Broth Serum
Mean SD (CV%) Mean SD (CV%)
Log E0 (CFU/mL) 2.65 0.42 1.79 0.64
Log Emax (CFU/mL) −5.57 0.80 −6.71 0.65
Log Emax - Log E0 (CFU/mL) −8.23 0.38 −8.50 0.01
Gamma 3.18 1.20 4.07 0.77
AUC24h/MIC for bacteriostatic action (h) 24.8 1.79 (7.2) 32.4 5.30 (16.4)
AUC24h/MIC50(h) 31.8 4.09 (12.9) 45.6 9.45 (20.7)
AUC24h/MIC for bactericidal action (h) 42.0 4.34 (10.3) 48.7 6.58 (13.5)
AUC24h/MIC for 4 log10 reduction (h) 54.0 7.04 (13.0) 55.5 6.43 (11.6)
E0 = difference in number of organisms (CFU/mL) in control sample in absence of drug between time 0 and 24 h; Emax = difference in number of organisms (CFU/
mL) in presence of marbofloxacin between time 0 and 24 h; AUC24/MIC50 = concentration producing reduction in count to 50% of the Emax; Gamma = slope of
the curve; detection limit = 33 CFU/mL
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on marbofloxacin PK in healthy pigs, aged 12, 16 and
27 weeks, administered intramuscularly at three dose rates
of 4, 8 and 16 mg/kg. PK/PD integration of data from these
studies is presented in a Additional file 1 to this paper.
Briefly, for both bacterial species and pigs aged 27 weeks,
Cmax/MIC90 ratios were 56, 105 and 258, respectively, for
marbofloxacin doses of 4, 8 and 16 mg/kg. Even average
concentrations over the 92 h period after dosing provided
Caverage/MIC90 ratios of 9.6, 19.7 and 39.1 for these dose
rates. Therefore, a preliminary prediction of likely success-
ful clinical outcome for doses of marbofloxacin in the range
4–16 mg/kg can be made for pig pneumonia caused by the
pathogens, A. pleuropneumoniae and P. multocida.
PK/PD modelling and breakpoint determination
PK/PD integration is not a precise tool; it should be
regarded as a first initial step in predicting efficacy in
clinical use. It is especially useful when correlated with
outcome in clinical trials. However, the next essential step
is to define PK/PD breakpoints for each antimicrobial
drug acting against representative isolates of each patho-
genic species. PK/PD modelling describes the whole sweep
of the concentration-effect relationship. Therefore, any
pre-determined level of activity, ranging from bacteriosta-
sis to virtual eradication, indicated by the breakpoint
AUC24h/MIC index, can be determined. Applying PK/PD
breakpoints for indices such as AUC24h/MIC, derived
from PK/PD modelling, with MCS provides an approach
to dose prediction, which takes account of animal species
based PK, wild-type MIC distributions, protein binding
and breakpoints for specific bacterial species. From such
time-kill studies, numerical values of PK/PD breakpoints
have been determined by PK/PD modelling by previous
workers [7–10, 12, 13, 21, 25, 33].
In this study, breakpoint values for each level of
growth inhibition, 0log10, 3log10 and 4log10 reductions in
count, were broadly similar for the two growth matrices.
This is not unexpected because, although MICs in broth
and serum differed, the breakpoint values are based on
MIC multiples. AUC24h/MIC ratios were similar for
broth and serum for each level of kill, being based on
MIC values separately for each matrix. Moreover, inter-
isolate variability in PK/PD breakpoint values was small
to moderate.
Dosage prediction
PK/PD breakpoints were used with wild type MIC distri-
butions of susceptible pathogens and literature PK data,
to conduct MCS to predict doses providing a range of
pre-determined levels of kill. The deterministic approach
Table 3 Predicted once daily doses calculated by deterministic
approach
Level of kill Predicted daily doses (mg/kg)
P. multocida A. pleuropneumoniae
Bacteriostatic 0.19 0.15
Bactericidal 0.41 0.26
4log10 count reduction 0.65 0.32
Table 4 Predicted once daily doses of marbofloxacin at steady
state in pigs of three ages (weeks): 27 (A), 16 (B) and 12 (C)a
Predicted daily
doses
(mg/kg)
Target Attainment Rate
50% 90%
A.
P. multocida Bacteriostatic 0.08 0.19
Bactericidal 0.18 0.43
Virtual eradication 0.28 0.67
A. Pleuropneumoniae Bacteriostatic 0.07 0.17
Bactericidal 0.12 0.29
4log10 reduction 0.15 0.36
B.
P. multocida Bacteriostatic 0.09 0.21
Bactericidal 0.20 0.45
Virtual eradication 0.32 0.72
A. pleuropneumoniae Bacteriostatic 0.08 0.17
Bactericidal 0.13 0.30
4log10 reduction 0.17 0.37
C.
P. multocida Bacteriostatic 0.13 0.28
Bactericidal 0.28 0.59
Virtual eradication 0.45 0.94
A. pleuropneumoniae Bacteriostatic 0.10 0.22
Bactericidal 0.18 0.39
4log10 reduction 0.22 0.48
aMonte Carlo simulation to achieve 50 and 90% target attainment rates at
steady state for three levels of bacterial kill
Table 5 Predicted doses of marbofloxacin for three durations of
activity (24, 48 and 72 h)a
Target Attainment Rate
P.multocida A.pleuropneumoniae
Dose duration Level of bacterial kill 50% 90% 50% 90%
0-24 h Bacteriostatic 0.12 0.29 0.03 0.07
Bactericidal 0.27 0.64 0.05 0.12
4 log10 reduction 0.43 1.01 0.06 0.14
0-48 h Bacteriostatic 0.19 0.44 0.16 0.39
Bactericidal 0.40 0.95 0.28 0.66
4 log10 reduction 0.64 1.51 0.34 0.82
0-72 h Bacteriostatic 0.26 0.60 0.22 0.53
Bactericidal 0.56 1.31 0.38 0.92
4 log10 reduction 0.88 2.08 0.47 1.14
aMonte Carlo Simulation to achieve 50 and 90% target attainment rates for
two levels of bacterial kill and three action durations
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provided an estimate of once daily doses at steady state.
It is based on MIC90 for each pathogen and average
values for other variables. It provides an initial indication
of likely effective dosage, but does not take account
either of variability or incidence of each input variable
and in this study. Predicted daily doses were less than
0.5 mg/kg for a bactericidal kill against both pathogens.
Nevertheless, the deterministic approach comprises an
initial indication, prior to estimation of population doses
for each selected TAR. The latter is a dose encompassing
a given percentile of the target population, for example,
50 or 90% and for three pre-determined levels of bacter-
ial kill and for both a single dose and a daily dose at
steady state. Monte Carlo simulations predict doses
which allow for incidence within MIC distributions and
encompass best, worst and all intermediate values for
distributions of Cl/F and breakpoint AUC24h/MIC ratios.
Furthermore, basing potency estimates on serum as a
growth matrix, as in this study, has greater relevance to
disease conditions than MICs determined in broths.
Nevertheless, it is recognised that serum, although pre-
ferred to broth for MIC determination, is similar but not
identical in composition to the biophase at infection
sites, for example pulmonary epithelial lining fluid.
As discussed by Martinez et al. [8] it is the exposure
achieved after the first dose, which is most relevant in
determining therapeutic outcome. In this study, low
marbofloxacin doses were predicted for a greater than
bactericidal action, with 90% TAR in both species; for
72 h and a 4log10 reduction in count, the predicted
doses were 2.08 and 1.14 mg/kg, respectively, for P.
multocida and A. pleuropneumoniae. Both dosages are
less than the dosages of 4, 8 and 16 mg/kg studied by
Schneider et al. [1]. To achieve a bactericidal action
(3log10 reduction in count) for P. multocida for 90%
TAR, once daily doses at steady state were even lower,
0.43 mg/kg for P. multocida and for A. pleuropneumo-
niae 0.29 mg/kg for pigs aged 27 weeks.
These predicted doses are lower than those of 2.5 mg/kg
and 8 mg/kg investigated by Ding et al. [3] and Ferran et
al. [34] as well as the 2 mg/kg recommended dose for
several licensed marbofloxacin products. Ferren et al.
[34] suggested that even lower doses of marbofloxacin
could potentially eradicate low counts (105 CFU/mL)
in the lung, while having a minimal impact on the
microbiota of the large intestine. On the other hand,
Vallé et al. [35] validated for the bovine pneumonia
pathogens, P. multocida and Mannheimia haemoly-
tica, the concept of a single high dose of marbofloxa-
cin compared to a daily dose of 2 mg/kg for 3–5 days.
A bactericidal effect against bovine P. multocida was
achieved within one hour, when marbofloxacin was
administered at five times the recommended daily
dose (10 mg/kg).
The present study illustrates the principles of using MCS
to predict dosages of marbofloxacin for the treatment of
pneumonia in the young pig. The proposed dosage regimen
is for A. pleuropneumoniae and P.multocida induced pneu-
monias only. For other organisms, independent PK/PD
studies will be required. However, in future studies it will
be important to extend the present findings for A. pleurop-
neumoniae and P.multocida also. Whilst the inter-isolate
variability in PK/PD breakpoint values for bacteriostatic
and bactericidal levels of kill was small in the present study,
estimates were based on only six isolates for each species.
Moreover, the time-kill studies generating the PK/PD
breakpoints used fixed drug concentrations (eight multiples
of MIC) for a fixed time period. In clinical use, on the other
hand, plasma drug concentrations first increase and then
decrease after intramuscular dosing, exposing organisms to
a continuously variable concentration. A third consider-
ation is the relatively small number of isolates in the report
of de Jong et al. [29].
In future studies, these concerns could be addressed by
increasing numbers of isolates in field distribution studies
and in PK/PD breakpoint estimation studies. Moreover, ex-
posure of organisms to varying drug concentrations could
be addressed by use for example of hollow fibre methods to
simulate in vivo patterns of change in concentration with
time. Furthermore, marbofloxacin PK data were used as
mean and standard deviation values from the literature. In
future studies, it will be useful to incorporate individual ani-
mal PK data in the MCSs, and, in particular it will be help-
ful to use population PK data obtained in clinically ill pigs.
Finally, the methodology in this study did not consider the
contribution to pathogen elimination by the body’s natural
defence mechanisms, which are known to be important in
immune competent clinical subjects. In addition, potentially
beneficial properties of antimicrobial drugs, such as immu-
nomodulatory and anti-inflammatory actions are of import-
ance for some drug classes. Finally, dose prediction studies,
as reported in this manuscript, should always be correlated
with clinical and bacteriological outcomes in animal disease
models and clinical trials [7, 11–13].
Conclusions
Predicted doses for marbofloxacin for treatment of
respiratory tract infections in the pig, caused by P. multo-
cida or A. pleuropneumoniae, were determined by gener-
ating PK/PD breakpoints for several levels of kill, based on
modelling PK and PD data. These breakpoint values were
used with published MIC distribution data [29] and PK
data [1] to determine dosages for three levels of kill, and
for once daily doses at steady state and for single doses
with both 50% and 90% target Attainment Rates. The find-
ings illustrate the value and principle of using Monte
Carlo simulation for determination of optimal doses for a
range of outcomes.
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